Why should I consider a myeloma clinical trial?

Trials are a standard part of excellent myeloma care, not an experiment on a guinea pig. They can give you early access to new drugs or combinations before those treatments are widely available, plus close monitoring by specialists. Broader enrollment is also how life expectancy for myeloma has tripled in recent years.

Will I receive a placebo?

In myeloma trials you will never receive no treatment or a sugar pill alone. You always receive either the new experimental therapy or the current best standard of care. Before you join, a research team explains every detail, risk, and benefit through informed consent.

What is the difference between trial phases?

Phase 1 studies are small, usually fewer than 50 patients, and focus on the safest dose and side effects. Phase 2 studies test how well the drug fights your type of cancer. Phase 3 studies are large, often more than 200 patients, and compare the new treatment with standard care; if it is better, the FDA may approve it.

Are clinical trials only a last resort?

No. Guidelines recommend considering a trial at every stage, from smoldering myeloma to first treatment to late relapse. Ask your doctor whether a study fits your situation whenever a new treatment decision is being made.

Can I leave a trial if I change my mind?

Yes. Participation is strictly voluntary. You have the right to leave at any time and return to standard treatments.

Back to Guidelines

First-Line TreatmentRelapse Management

Clinical Trials

Name: Clinical Trials | CMDN
Creator: CMDN Editorial Team

Accessing Tomorrow's Treatments Today

Medical Disclaimer: The following content is compiled based on the latest authoritative guidelines at home and abroad. It is for reference only for patients and their families and cannot replace the professional medical advice of the attending physician. Please be sure to follow the doctor's advice for the treatment plan.

What is a myeloma clinical trial?

Participating in Phase 1 to 3 clinical trials gives patients cost-free access to cutting-edge immunotherapies including CAR-T and bispecific antibodies, with 100% of investigational drug and testing costs fully covered by study sponsors.

What should I discuss before considering a trial?

(1) Why Participation is Encouraged (Early Access to Novel Therapies): Clinical trials are the engine of medical progress. By participating, you have the unique opportunity to be among the very first to receive the newest, most innovative drugs or drug combinations before they are commercially available on the market. Additionally, you will receive incredibly close monitoring from top myeloma experts. The more patients who enroll, the faster researchers can find answers, which is exactly how the life expectancy for myeloma patients has tripled in recent years.
(2) How Patient Safety and Ethics are Maintained: Your safety is always the highest priority. Before any new drug is ever given to a human, it must pass rigorous laboratory and animal testing (preclinical studies) to prove it is active and safe. If you decide to join a trial, you will go through a strict "informed consent" process; a research team will explain every detail, risk, and benefit before you sign anything. Furthermore, in myeloma trials, you will never receive "no treatment" or just a sugar pill (placebo) alone. You will always receive either the promising new experimental therapy or the absolute best standard of care currently available. Finally, participation is strictly voluntary—you have the absolute right to leave the trial at any time and return to standard treatments.
(3) The Difference Between Early-Phase and Late-Phase Trials: Clinical trials are conducted in careful, step-by-step phases to ensure safety:
- Phase 1: These are small studies (usually fewer than 50 patients) focused primarily on finding the safest dosage and monitoring for side effects.
- Phase 2: These moderately sized studies focus on testing how effectively the drug fights your specific type of cancer.
- Phase 3: These are large studies (often involving more than 200 patients) that directly compare the new drug against the current standard of care. If the new treatment proves to be better, the U.S. Food and Drug Administration (FDA) may officially approve it.
(4) The Importance of Asking Your Doctor at Every Stage: A common misconception is that clinical trials are only a "last resort" when all other treatments have failed. In reality, guidelines strongly recommend that clinical trials be considered at every stage of the disease—from asymptomatic smoldering myeloma, to your very first frontline treatment, to late-stage relapsed disease. You should feel empowered to ask your doctor, "Is there a clinical trial that might fit my situation?" every time a new treatment decision needs to be made.

The above content is sourced from the following references

Patient Handbook
MULTIPLE MYELOMA TREATMENT OVERVIEW
MULTIPLE MYELOMA NEWLY DIAGNOSED
NCCN Guidelines for Patients® Multiple Myeloma
Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline

Your myeloma care companion

CMDN Care · Myeloma Companion

Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.

Open CMDN Care How CMDN Care works

Lab report OCR

Review results extracted from your reports.

Biomarker trends

Keep follow-up results in one place.

Visit preparation

Bring your questions to your care team.

Your share could light up hope for another patient 💛

FAQs

Why should I consider a myeloma clinical trial?: Trials are a standard part of excellent myeloma care, not an experiment on a guinea pig. They can give you early access to new drugs or combinations before those treatments are widely available, plus close monitoring by specialists. Broader enrollment is also how life expectancy for myeloma has tripled in recent years.
Will I receive a placebo?: In myeloma trials you will never receive no treatment or a sugar pill alone. You always receive either the new experimental therapy or the current best standard of care. Before you join, a research team explains every detail, risk, and benefit through informed consent.
What is the difference between trial phases?: Phase 1 studies are small, usually fewer than 50 patients, and focus on the safest dose and side effects. Phase 2 studies test how well the drug fights your type of cancer. Phase 3 studies are large, often more than 200 patients, and compare the new treatment with standard care; if it is better, the FDA may approve it.
Are clinical trials only a last resort?: No. Guidelines recommend considering a trial at every stage, from smoldering myeloma to first treatment to late relapse. Ask your doctor whether a study fits your situation whenever a new treatment decision is being made.
Can I leave a trial if I change my mind?: Yes. Participation is strictly voluntary. You have the right to leave at any time and return to standard treatments.

References used for this guide

Sincere thanks to the following authoritative institutions
for their academic support:

Lighting the hope of survival
for myeloma patients globally

Disclaimer: All disease knowledge, guideline interpretations, and treatment processes provided on this site are for learning and reference only, and do not constitute any medical advice or professional diagnosis. The condition of each patient is unique. For specific treatment plans and medication decisions, please be sure to follow the guidance of your attending physician or professional medical team.

This article is reviewed and published by the CMDN Editorial Team

Last updated: 2026-10-03

Get Support